Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Chemoprevention of prostate cancer.

Walsh PC.

N Engl J Med. 2010 Apr 1;362(13):1237-8. doi: 10.1056/NEJMe1001045. No abstract available.

PMID:
20357287
2.

Dutasteride and prostate cancer.

Klotz L.

N Engl J Med. 2010 Aug 19;363(8):794; author reply 795-6. No abstract available.

PMID:
20842791
3.

Dutasteride and prostate cancer.

Garattini S, Bertele' V.

N Engl J Med. 2010 Aug 19;363(8):794; author reply 794-6. No abstract available.

PMID:
20842790
4.

Dutasteride and prostate cancer.

Schröder FH, Roobol MJ.

N Engl J Med. 2010 Aug 19;363(8):793-4; author reply 794-5. No abstract available.

PMID:
20842789
5.

Dutasteride and prostate cancer.

Kiemeney LA, Bosland MC.

N Engl J Med. 2010 Aug 19;363(8):793; author reply 794-5. doi: 10.1056/NEJMc1005498. No abstract available.

6.

Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.

Orvieto M, Eggener S.

Eur Urol. 2009 May;55(5):1073-4. doi: 10.1016/j.eururo.2009.01.038. Epub 2009 Feb 5. No abstract available.

PMID:
19200640
7.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

8.

Prevention of prostate cancer with finasteride.

Ross RK, Skinner E, Cote RJ.

N Engl J Med. 2003 Oct 16;349(16):1569-72; author reply 1569-72. No abstract available.

PMID:
14562807
9.

Chemoprevention of prostate cancer.

Stephenson AJ, Abouassaly R, Klein EA.

Urol Clin North Am. 2010 Feb;37(1):11-21, Table of Contents. doi: 10.1016/j.ucl.2009.11.003. Review.

PMID:
20152515
10.

Prevention of prostate cancer with finasteride.

Burke HB.

N Engl J Med. 2003 Oct 16;349(16):1569-72; author reply 1569-72. No abstract available.

PMID:
14562806
11.

Thoughts on finasteride for benign prostatic hyperplasia.

Anand A.

Am Fam Physician. 1993 Sep 15;48(4):582, 588. No abstract available.

PMID:
7691035
12.

New tests for prostate cancer may be nearing the clinic.

Tuma RS.

J Natl Cancer Inst. 2010 Jun 2;102(11):752-4. doi: 10.1093/jnci/djq210. Epub 2010 May 24. No abstract available.

PMID:
20498428
13.

The potential application of finasteride for chemoprevention of prostate cancer.

Gormley GJ, Brawley O, Thompson I.

Ann N Y Acad Sci. 1995 Sep 30;768:163-9. Review. No abstract available.

PMID:
8526345
14.

The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.

Reed AB, Parekh DJ.

Curr Opin Urol. 2009 May;19(3):238-42. doi: 10.1097/MOU.0b013e328329eb29. Review.

PMID:
19318950
15.

Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors.

Gormley GJ.

J Cell Biochem Suppl. 1992;16H:113-7. Review.

PMID:
1283894
16.

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, Rittmaster R; REDUCE Study Group.

J Urol. 2004 Oct;172(4 Pt 1):1314-7.

PMID:
15371831
17.

Pharmacological approaches to reducing the risk of prostate cancer.

Rittmaster RS, Fleshner NE, Thompson IM.

Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Review.

PMID:
19200641
18.

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

Musquera M, Fleshner NE, Finelli A, Zlotta AR.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073.

PMID:
18588452
19.

A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.

Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R.

Prostate. 2009 Jun 1;69(8):895-907. doi: 10.1002/pros.20939. Review.

PMID:
19267353
20.

Overview of pivotal studies for prostate cancer risk reduction, past and present.

Andriole GL.

Urology. 2009 May;73(5 Suppl):S36-43. doi: 10.1016/j.urology.2009.02.017. Review. Erratum in: Urology. 2010 Sep;76(3):771.

PMID:
19375625

Supplemental Content

Support Center